Aquestive Therapeutics Inc. (AQST)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
Aquestive Therapeutics (AQST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript
Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript
Aquestive Therapeutics Q1 Earnings Call Highlights
Aquestive Therapeutics NASDAQ: AQST said it remains on track to resubmit its new drug application for Anaphylm, its epinephrine sublingual film for severe allergic reactions, in the third quarter of 2026, while reporting higher first-quarter revenue and a narrower net loss.
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.24 per share a year ago.
Will Aquestive Therapeutics (AQST) Report Negative Q1 Earnings? What You Should Know
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval
Aquestive Therapeutics remains a Buy, with an $8 fair value estimate and 87% upside, driven by Anaphylm's FDA approval prospects. Anaphylm's CRL issues are addressable, focused on packaging and labeling, not efficacy or safety, with a pivotal PK study planned for Q2–Q3 2026. I model 95% US and ~80% international adoption probability for Anaphylm and profitability by 2029, although they will likely need more financing by the end of 2027.
Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call Transcript
Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call Transcript
Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.19 per share a year ago.
Aquestive Therapeutics, Inc. (AQST) Discusses FDA Complete Response Letter and Next Steps for Anaphylm Epinephrine Sublingual Film Transcript
Aquestive Therapeutics, Inc. (AQST) Discusses FDA Complete Response Letter and Next Steps for Anaphylm Epinephrine Sublingual Film Transcript
